Journal
SEMINARS IN FETAL & NEONATAL MEDICINE
Volume 24, Issue 3, Pages 182-188Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.siny.2019.05.002
Keywords
Antenatal corticosteroids; Preterm birth; Controversy; Betamethasone; Dexamethasone
Categories
Ask authors/readers for more resources
Antenatal corticosteroids (ACS) successfully reduce the rates of neonatal mortality and morbidity after preterm birth. However, this translational success story is not without controversies. This chapter explores some contemporary controversies with ACS, including the choice of corticosteroid, use in threatened preterm birth less than 24 weeks' gestation, use in late preterm birth, use at term before cesarean delivery, and issues surrounding repeated and rescue dosing of antenatal corticosteroids. The use of ACS in special populations is also discussed. Finally, areas of future research in ACS are presented, focusing on the ability to individualize therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available